| Autor: |
Boareto AC; Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil. boaretoana@gmail.com, Muller JC, Bufalo AC, Botelho GG, de Araujo SL, Foglio MA, de Morais RN, Dalsenter PR |
| Jazyk: |
angličtina |
| Zdroj: |
Reproductive toxicology (Elmsford, N.Y.) [Reprod Toxicol] 2008 Feb; Vol. 25 (2), pp. 239-46. Date of Electronic Publication: 2007 Nov 17. |
| DOI: |
10.1016/j.reprotox.2007.11.003 |
| Abstrakt: |
Artemisinin compounds are important for treating multidrug-resistant malaria; however, the possible resorption and abnormalities observed in animal reproduction studies may contraindicate artemisinin use during the first trimester. To evaluate whether artemisinin interferes with developmental outcomes at different periods of pregnancy, Wistar rats were treated by gavage with increasing doses of 7, 35 and 70 mg/kg/day from gestational day [GD] 7 to 13 or 14 to 20. Viable embryos and post-implantation losses, and progestagens and testosterone levels, were monitored in the former treatment group and pregnancy and outcomes data, post-implantation losses and male and female developmental endpoints of the offspring were evaluated in the latter treatment group. Results indicate toxicity for both periods of treatment, with lower sensitivity at later stages of pregnancy. The results showed that dosing with 35 or 75 mg/kg of artemisinin caused high percentages of post-implantation losses that correlated with a trend to lower maternal progestagens and a significant maternal testosterone decrease. These findings demonstrate that oral administration of artemisinin can adversely effect post-implantation development and pregnancy in the rat. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect